NEW YORK (360Dx) – When NeoGenomics announced plans to acquire Genoptix late last month, company executives made clear what Genoptix would bring to the table: community oncologists.

"While we have made some meaningful strides in building our community oncology practice business over the past two years, it is still quite small. With the addition of Genoptix, that will change," NeoGenomics Chairman and CEO Douglas VanOort said in a conference call following the acquisition.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.